Sanguine Medical Ltd Release: Vivostat Co-Delivery: Cutting-Edge Burn Treatment On Trial

LONDON--(BUSINESS WIRE)--Some burns are too difficult or infected to treat using traditional surgery without the patient going through multiple procedures, pain and discomfort or even death.

“The Vivostat co-delivery system makes sure that the cells stay on the patient and do not run off. Early results show we can control the outcome better and get good graft take and healing.”

The pioneering co-delivery using the patient’s own blood and other substance has been utilised for many years in wound therapy and is being used for the first time with skin cells at the Queen Elizabeth Hospital Birmingham on burns patients. Though it is still in the early stages of assessment, surgeons claim this non-invasive form of surgery may be the only lifeline available to patients suffering from extensive burns.

“We regularly use ‘spray-on skin cell’ technology here in Birmingham. One of the issues up until now has been getting the cells to stick onto the wound,” says Lt Col Prof Steven Jeffery, who is pioneering the treatment on burns patients at The Queen Elizabeth Hospital Birmingham.

“The cells are expensive and seeing them run off the wound away from the patient can be heart-breaking.”

“The Vivostat co-delivery system makes sure that the cells stay on the patient and do not run off. Early results show we can control the outcome better and get good graft take and healing.”

The cells are protected by fibrin made from the patient’s blood using the unique fully automated Vivostat Processing System and applied using the Vivostat Co-Delivery Applicator which keeps the skin cells in place while creating an optimal wound healing environment providing tissue adherence, growth and repair.

While the Vivostat treatment has the potential to improve healing, infection rates and improve quality of life, its precise application means it is suitable for most burn patients whose wounds have not healed or for those suffering from chronic wound problems. Moreover, Vivostat is shown to be effective in reducing (or in same cases eliminating) the use of staples making it cost / time effective and less painful for the patient.

This innovative treatment and the early stage success of it has gained interest among other renowned burns centres not only in the UK but also in Europe. Currently Vivostat’s effectiveness is being evaluated in London.

With such a great response and enthusiasm from health care professionals, Vivostat has been encouraged to be present for the first time at the Annual Meeting for the British Burns Association taking place this year in Newcastle from the 11th to 13^th of May 2016 where Lt Col Prof Steven Jeffery’s first co-delivery case abstract poster will be presented.

Vivostat www.vivostat.com has developed the revolutionary Co-Delivery system that makes it possible to co-deliver a desired substance (drugs, stem cells etc.) with Vivostat^® Fibrin Sealant or Vivostat PRF^® (Platelet Rich Fibrin).